- Home
- OPFI vs ETON Comparison
OPFI vs ETON Comparison
Compare OPFI & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPFI | ETON |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | 410 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 801.0M | 872.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | OPFI | ETON |
|---|---|---|
| Price | $9.04 | $42.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $14.25 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 654.9K | 524.8K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | $97.52 | $40.90 |
| Revenue Next Year | $10.95 | $47.23 |
| P/E Ratio | ★ $67.57 | $882.80 |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $7.36 | $13.78 |
| 52 Week High | $12.60 | $44.91 |
Technical Indicators
Market Signals| Indicator | OPFI | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 47.62 | 69.26 |
| Support Level | $8.78 | $16.02 |
| Resistance Level | $9.51 | N/A |
| Average True Range (ATR) | 0.31 | 2.16 |
| MACD | -0.08 | 0.44 |
| Stochastic Oscillator | 18.22 | 84.11 |
Price Performance
Historical ComparisonAbout OPFI OppFi Inc.
OppFi Inc. is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to expand credit access for everyday Americans. It recognizes revenue from finance charges on installment and SalaryTap contracts using the interest method.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.